title: Feasibility of Chemotherapy in Patients with Inflammatory Bowel Disease-Related Gastrointestinal Cancer.
abstract: OBJECTIVE
  Long-standing inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn disease (CD), is a known risk factor for gastrointestinal (GI) cancer, especially colorectal cancer (CRC). However, the feasibility of chemotherapy for IBD-related GI cancer is not well understood in terms of efficacy and adverse events, because there are fewer GI cancer patients with IBD than without IBD.
  
  
  METHODS
  We retrospectively analyzed the medical records of eight IBD patients (CD = 5 and UC = 3) who received chemotherapy for IBD-related GI cancer between April 2003 and March 2013.
  
  
  RESULTS
  The most common gastrointestinal adverse event was diarrhea (75%); 38% of patients experienced grade 3 diarrhea. Moreover, all grade 3 diarrhea occurred in patients with CD. The most common hematologic adverse events were anemia (75%), leukopenia (38%), and neutropenia (30%); 25% of patients experienced grade 3 neutropenia. The other severe adverse events were grade 3 AST and ALT elevation (13%).
  
  
  CONCLUSIONS
  In this study, the incidence of grade 3 diarrhea was higher in patients with CD. The length and dysfunction of the small intestine is the most likely reason that diarrhea occurred more frequently in patients with CD.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Naito
authors.forename: Tsunekazu
authors.initials: T
authors.lastname: Mizushima
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Takeyama
authors.forename: Daisuke
authors.initials: D
authors.lastname: Sakai
authors.forename: Mamoru
authors.initials: M
authors.lastname: Uemura
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Kudo
authors.forename: Junichi
authors.initials: J
authors.lastname: Nishimura
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Shinzaki
authors.forename: Taishi
authors.initials: T
authors.lastname: Hata
authors.forename: Taro
authors.initials: T
authors.lastname: Sato
authors.forename: Ichiro
authors.initials: I
authors.lastname: Takemasa
authors.forename: Kiyokazu
authors.initials: K
authors.lastname: Nakajima
authors.forename: Hideki
authors.initials: H
authors.lastname: Iijima
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Yamamoto
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Doki
authors.forename: Masaki
authors.initials: M
authors.lastname: Mori
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003093:Colitis, Ulcerative / Q000150:complications* / Q000175:diagnosis; D003424:Crohn Disease / Q000150:complications* / Q000175:diagnosis; D003967:Diarrhea / Q000139:chemically induced; D005240:Feasibility Studies; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome